GNFTF Projected Dividend Yield
GENFIT SA ( OTCBB : GNFTF )Genfit is a late-stage clinical biopharmaceutical company dedicated to the discovery and development of drug candidates and diagnostic solutions targeting metabolic and liver-related diseases. Co. is engaged in the field of nuclear receptor-based drug discovery. Co. is evaluating its drug candidate, elafibranor, in a Phase 3 clinical trial as a potential treatment for nonalcoholic steatohepatitis, and as a potential treatment for primary biliary cholangitis. Co. is also developing a clinical-stage program based on drug repositioning to develop an anti-fibrotic drug. Co.'s primary drug candidate in this program, nitazoxanide, is an approved anti-parasitic agent. 20 YEAR PERFORMANCE RESULTS |
GNFTF Dividend History Detail GNFTF Dividend News GNFTF Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |